Genes,DisGeNET_Term,DisGeNET_Pvalue_Adjusted,GeDiPNet_Term,GeDiPNet_Pvalue_Adjusted,Orphanet_Term,Orphanet_Pvalue_Adjusted,Virus_Host_Term,Virus_Host_Pvalue_Adjusted,Host organism(s)_Intact,Confidence value(s)_Intact,Taxid interactor A_Intact,Taxid interactor B_Intact
AANAT,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; melanoma; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999,,,,,,,,,,
ABCB1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Hematopoietic Neoplasms; Medulloblastoma; Epithelial ovarian cancer; Brain Tumor, Primary",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0334891258932371; 0.0354767239335874; 0.0387439397151409; 0.044151975756427,Breast Carcinoma; Esophagus Neoplasm; Marfan Syndrome; Mammary Neoplasms; Anaplastic Carcinoma; Breast Cancer,0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0402286636010764,,,,,,,,
ABCC2,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Fibrosarcoma; Carcinogenesis; Malignant neoplasm of ovary; Hematopoietic Neoplasms; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0334891258932371; 0.0387439397151409,Esophagus Neoplasm,0.0102679590519094,Autosomal recessive infantile hypercalcemia ORPHA:300547,0.0083045131203191,,,,,,
ACSL5,Colorectal Carcinoma; Epithelioma; Colorectal Cancer; Adenocarcinoma; Carcinogenesis,0.0034602840073026; 0.0149002095788623; 0.0149315928814189; 0.0155921563748247; 0.0228075668512991,,,,,,,In vitro,0.35,chemical synthesis,Homo sapiens
ACTA2,Mammary Neoplasms; Breast Carcinoma; Adenocarcinoma; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0155921563748247; 0.0191435238361999,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer; Lymphocytic Leukemia,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0487679768343083,,,,,Homo sapiens HEK293 embryonic kidney cell;In vitro;yeasx,0.35;0.37,Dengue virus 2;Homo sapiens;chemical synthesis;hhv11,Homo sapiens;Yersinia pestis
ADAM15,Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Epithelioma; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999,,,,,,,yeasx,0.37,Homo sapiens,Bacillus anthracis
ADAMTS14,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,,,,,,,,
ADAMTS15,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0042545616049287; 0.0149315928814189,,,"SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Early-onset nuclear cataract ORPHA:98991; Craniosynostosis, Boston type ORPHA:1541; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Parietal foramina with clavicular hypoplasia ORPHA:251290; Congenital cataract microcornea with corneal opacity ORPHA:289499; Dermatofibrosarcoma protuberans ORPHA:31112; Tetralogy of Fallot ORPHA:3303",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0277610005156803,,,,,,
AFAP1L2,Colorectal Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Malignant neoplasm of stomach; Carcinogenesis,0.0034602840073026; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991,,,,,,,,,,
AMOTL2,,,,,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; SIX2-related frontonasal dysplasia ORPHA:488437; Auriculocondylar syndrome ORPHA:137888; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Severe generalized junctional epidermolysis bullosa ORPHA:79404; 20p12.3 microdeletion syndrome ORPHA:261295; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Myelodysplastic syndrome ORPHA:52688; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Unverricht-Lundborg disease ORPHA:308; Waardenburg syndrome type 2 ORPHA:895; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Craniosynostosis, Boston type ORPHA:1541; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Hereditary papillary renal cell carcinoma ORPHA:47044; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Nance-Horan syndrome ORPHA:627; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Oculocutaneous albinism type 3 ORPHA:79433; Osteofibrous dysplasia ORPHA:488265; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Parietal foramina with clavicular hypoplasia ORPHA:251290; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Primary CD59 deficiency ORPHA:169464; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Congenital cataract microcornea with corneal opacity ORPHA:289499; Congenital diaphragmatic hernia ORPHA:2140; Dermatofibrosarcoma protuberans ORPHA:31112; Hypoplastic left heart syndrome ORPHA:2248; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Matthew-Wood syndrome ORPHA:2470; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; Trichorhinophalangeal syndrome type 2 ORPHA:502; BOR syndrome ORPHA:107; Erythrokeratodermia variabilis ORPHA:317; Tetralogy of Fallot ORPHA:3303",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0083744975290613; 0.0092060390928213; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.0277610005156803,,,yeasx,0.37;0.56,Homo sapiens,Homo sapiens;Saccharomyces cerevisiae
APOBEC3B,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,,,,,,,,
APOLD1,Adenocarcinoma,0.0155921563748247,,,,,,,,,,
ARL2BP,Stomach Carcinoma; Carcinogenesis,0.0149315928814189; 0.0228075668512991,,,,,,,yeasx,0.56,Homo sapiens,Homo sapiens
ARRDC4,,,,,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205,0.0180064224283883; 0.0180064224283883,,,,,,
B3GLCT,,,Anomalous Pulmonary Artery,0.0075861267486594,,,,,,,,
BBC3,Colorectal Carcinoma; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Hematopoietic Neoplasms; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0334891258932371; 0.0387439397151409,Esophagus Neoplasm,0.0102679590519094,,,,,,,,
BFSP1,,,,,"Early-onset nuclear cataract ORPHA:98991; Craniosynostosis, Boston type ORPHA:1541; Parietal foramina with clavicular hypoplasia ORPHA:251290",0.0179885731122231; 0.0180064224283883; 0.0180064224283883,,,,,,
BMF,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,Lymphocytic Leukemia,0.0487679768343083,,,,,,,,
C1QL1,Breast Carcinoma; Malignant neoplasm of breast,0.0042545616049287; 0.0191435238361999,,,,,,,Homo sapiens A549 lung carcinoma cell,0.35,Human SARS coronavirus;SARS-CoV-2,Homo sapiens
CA11,Breast Carcinoma; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis,0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991,,,,,,,,,,
CA2,Breast Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of stomach,0.0042545616049287; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999,Esophagus Neoplasm,0.0102679590519094,,,,,yeasx,0.37,Homo sapiens,coxbu
CASP7,Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,,,,,In vitro,0.4;0.44,Homo sapiens;chemical synthesis,Homo sapiens
CCND1,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; Pre B-cell acute lymphoblastic leukemia; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Urologic Neoplasms; Hematopoietic Neoplasms; Medulloblastoma; Epithelial ovarian cancer; Brain Tumor, Primary; Skin carcinoma; Cancer of Urinary Tract",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0189794808441368; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0314665934969085; 0.0334891258932371; 0.0354767239335874; 0.0387439397151409; 0.044151975756427; 0.0482468351695405; 0.0492766532827251,Breast Carcinoma; Esophagus Neoplasm; Urinary Tract Cancer; Marfan Syndrome; Mammary Neoplasms; Anaplastic Carcinoma; Breast Cancer; Lymphocytic Leukemia,0.0075861267486594; 0.0102679590519094; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0402286636010764; 0.0487679768343083,"Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Auriculocondylar syndrome ORPHA:137888; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Rieger anomaly ORPHA:91483; Unverricht-Lundborg disease ORPHA:308; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; CHST3-related skeletal dysplasia ORPHA:263463; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Craniosynostosis, Boston type ORPHA:1541; Hereditary papillary renal cell carcinoma ORPHA:47044; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Osteofibrous dysplasia ORPHA:488265; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Parietal foramina with clavicular hypoplasia ORPHA:251290; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Dermatofibrosarcoma protuberans ORPHA:31112; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; BOR syndrome ORPHA:107",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111,,,,,,
CEACAM19,Breast Carcinoma; Malignant neoplasm of breast,0.0042545616049287; 0.0191435238361999,,,,,,,,,,
CENPE,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; melanoma; Malignant neoplasm of breast; Carcinogenesis,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991,,,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971,0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111,,,,,,
CHST11,Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Tumor Progression; Malignant neoplasm of breast; Malignant neoplasm of ovary,0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0191435238361999; 0.0277695594716545,,,,,,,,,,
CLSPN,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Malignant neoplasm of breast; Carcinogenesis,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0191435238361999; 0.0228075668512991,Breast Cancer,0.0402286636010764,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971,0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111,,,,,,
CNTNAP1,Breast Carcinoma; Pre B-cell acute lymphoblastic leukemia; Carcinogenesis,0.0042545616049287; 0.0189794808441368; 0.0228075668512991,Breast Carcinoma,0.0075861267486594,,,,,Homo sapiens,0.35,Human papillomavirus type 11;Human papillomavirus type 6b;ebvb9,Homo sapiens
COL12A1,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Malignant mesothelioma; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999,,,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; SIX2-related frontonasal dysplasia ORPHA:488437; Auriculocondylar syndrome ORPHA:137888; Peters anomaly ORPHA:708; Familial porencephaly ORPHA:99810; Severe generalized junctional epidermolysis bullosa ORPHA:79404; 20p12.3 microdeletion syndrome ORPHA:261295; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Isolated hyperchlorhidrosis ORPHA:542657; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Congenital short bowel syndrome ORPHA:2301; Myelodysplastic syndrome ORPHA:52688; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Waardenburg syndrome type 2 ORPHA:895; Bruck syndrome ORPHA:2771; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Autosomal recessive brachyolmia ORPHA:448242; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Hereditary papillary renal cell carcinoma ORPHA:47044; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Nance-Horan syndrome ORPHA:627; Oculocutaneous albinism type 3 ORPHA:79433; Osteofibrous dysplasia ORPHA:488265; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Primary CD59 deficiency ORPHA:169464; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Congenital cataract microcornea with corneal opacity ORPHA:289499; Congenital diaphragmatic hernia ORPHA:2140; Dermatofibrosarcoma protuberans ORPHA:31112; Familial primary localized cutaneous amyloidosis ORPHA:353220; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; Trichorhinophalangeal syndrome type 2 ORPHA:502; Erythrokeratodermia variabilis ORPHA:317; Ondine syndrome ORPHA:661",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.020072786018028,,,yeasx,0.37,Homo sapiens;Yersinia pestis,Bacillus anthracis;Homo sapiens;den27
COL5A2,Colorectal Carcinoma; Colorectal Cancer; Carcinogenesis,0.0034602840073026; 0.0149315928814189; 0.0228075668512991,,,"Atrial septal defect, ostium primum type ORPHA:99106; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; 20p12.3 microdeletion syndrome ORPHA:261295; Chondrosarcoma ORPHA:55880; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Tibial hemimelia ORPHA:93322; Congenital short bowel syndrome ORPHA:2301; Brachydactyly type A2 ORPHA:93396; Bruck syndrome ORPHA:2771; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Ischiovertebral syndrome ORPHA:85200; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Dermatofibrosarcoma protuberans ORPHA:31112; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; Ondine syndrome ORPHA:661; Tetralogy of Fallot ORPHA:3303",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.020072786018028; 0.0277610005156803,,,In vitro,0.35,chemical synthesis,Homo sapiens
CORO1A,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0308703957553632,Anaplastic Carcinoma,0.0402286636010764,,,,,Homo sapiens HepaRG hepatoma cell;yeasx,0.35;0.37,Hepatitis delta virus;Homo sapiens,Homo sapiens;Yersinia pestis
CPA4,,,,,Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Bamforth-Lazarus syndrome ORPHA:1226; Familial primary localized cutaneous amyloidosis ORPHA:353220,0.00518481975049; 0.0180064224283883; 0.0180064224283883,,,In vitro,0.62,Sabellastarte magnifica,Homo sapiens
CPEB4,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Adenocarcinoma; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999,,,,,,,Xenopus laevis,0.4,Homo sapiens,Homo sapiens
CTSD,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545,,,,,,,Homo sapiens QGY7703 hepatocellular carcinoma cell;In vitro;yeasx,0.35;0.37;0.44;0.56,Homo sapiens;Yersinia pestis;canen;chemical synthesis,Homo sapiens;chemical synthesis
CYP24A1,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; melanoma; Adenocarcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,Autosomal recessive infantile hypercalcemia ORPHA:300547; Bamforth-Lazarus syndrome ORPHA:1226,0.0083045131203191; 0.0180064224283883,,,,,,
CYP4F2,Ovarian Carcinoma; Malignant neoplasm of ovary,0.0034602840073026; 0.0277695594716545,,,,,,,yeasx,0.56,Homo sapiens,Homo sapiens
DEPDC1B,,,,,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971,0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111,,,,,,
DMBX1,Proliferative vitreoretinopathy,0.0182265588252201,,,,,,,,,,
DOCK11,Breast Carcinoma,0.0042545616049287,,,,,,,,,,
E2F7,Breast Carcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast,0.0042545616049287; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999,,,Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Stromme syndrome ORPHA:506307; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971,0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111,,,Homo sapiens U2OS osteosarcoma cell;In vitro,0.35;0.54,Homo sapiens,Homo sapiens
EFR3B,Breast Carcinoma,0.0042545616049287,Breast Carcinoma,0.0075861267486594,,,,,,,,
EHF,Ovarian Carcinoma; Tumor Progression; Stomach Carcinoma; Malignant mesothelioma; Malignant neoplasm of stomach; Carcinogenesis; Epithelial ovarian cancer,0.0034602840073026; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0387439397151409,,,Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Autosomal recessive infantile hypercalcemia ORPHA:300547; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403,0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883,,,In vitro,0.54,Homo sapiens,Homo sapiens
ENC1,Colorectal Carcinoma; Mammary Neoplasms; Carcinogenesis,0.0034602840073026; 0.0034602840073026; 0.0228075668512991,,,,,,,,,,
ENG,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Epithelial ovarian cancer",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0387439397151409,Anomalous Pulmonary Artery,0.0075861267486594,,,,,Homo sapiens;Homo sapiens HEK293 embryonic kidney cell;Homo sapiens HeLa S3 epitheloid cervical carcinoma cell;yeasx,0.35;0.37;0.4;0.5,Bacillus anthracis;Homo sapiens;Human papillomavirus type 11;Human papillomavirus type 6b;ade05;chemical synthesis;ebvb9,Homo sapiens
ESCO2,Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis,0.0149315928814189; 0.0191435238361999; 0.0228075668512991,,,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681,0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,,,,
FAM111B,,,,,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043,0.0083045131203191,,,yeasx,0.56,Homo sapiens,Homo sapiens
FGF19,Breast Carcinoma; Tumor Progression; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis,0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991,,,,,,,,,,
FHIT,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Urologic Neoplasms; Hematopoietic Neoplasms; Medulloblastoma; Epithelial ovarian cancer; Brain Tumor, Primary; Skin carcinoma; Cancer of Urinary Tract",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0314665934969085; 0.0334891258932371; 0.0354767239335874; 0.0387439397151409; 0.044151975756427; 0.0482468351695405; 0.0492766532827251,Urinary Tract Cancer; Anaplastic Carcinoma,0.0102679590519094; 0.0402286636010764,,,,,In vitro;yeasx,0.95,Homo sapiens,Homo sapiens
FRAT2,Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis,0.0149315928814189; 0.0191435238361999; 0.0228075668512991,,,,,,,,,,
FZD1,Breast Carcinoma; Invasive carcinoma of breast; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of esophagus; Medulloblastoma,0.0042545616049287; 0.0149002095788623; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0248454592431097; 0.0354767239335874,,,Unverricht-Lundborg disease ORPHA:308,0.0083744975290613,,,,,,
GAL,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991,,,,,,,,,,
GLI2,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive Ductal Breast Carcinoma; Tumor Progression; Stomach Carcinoma; melanoma; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Medulloblastoma; Skin carcinoma,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0354767239335874; 0.0482468351695405,,,"SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Congenital short bowel syndrome ORPHA:2301; Rieger anomaly ORPHA:91483; Early-onset nuclear cataract ORPHA:98991; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Nance-Horan syndrome ORPHA:627; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Retinal arterial tortuosity ORPHA:75326; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Congenital cataract microcornea with corneal opacity ORPHA:289499; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Piebaldism ORPHA:2884; BOR syndrome ORPHA:107; Ondine syndrome ORPHA:661; Tetralogy of Fallot ORPHA:3303",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.020072786018028; 0.0277610005156803,,,,,,
GPNMB,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Tumor Progression; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,,,,,,,,
GPR15,,,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944,0.0180064224283883; 0.0180064224283883,,,,,,
GPR37,melanoma; Malignant mesothelioma,0.0149315928814189; 0.0182265588252201,Lymphocytic Leukemia,0.0487679768343083,Oculocutaneous albinism type 3 ORPHA:79433; Congenital cataract microcornea with corneal opacity ORPHA:289499,0.0180064224283883; 0.0180064224283883,,,Homo sapiens A549 lung carcinoma cell;yeasx,0.35;0.37;0.56,Homo sapiens;SARS-CoV-2,Homo sapiens
GRAMD1B,,,Breast Carcinoma; Lymphocytic Leukemia,0.0075861267486594; 0.0487679768343083,,,,,,,,
H2AX,,,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,,,,,Homo sapiens;Homo sapiens CACO2 Caucasian colon adenocarcinoma cell;Homo sapiens HEK293T embryonic kidney cell;Homo sapiens SW480 adenocarcinoma cell;In vitro,0.35;0.4;0.46,Homo sapiens;SARS-CoV-2,Homo sapiens
HPSE,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Medulloblastoma; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0354767239335874; 0.0387439397151409,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,,,,,Homo sapiens diploid fibroblast;In vitro,0.35;0.4;0.44,chemical synthesis,Homo sapiens
HS3ST1,Tumor Progression,0.0149315928814189,,,,,,,,,,
HTATIP2,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; melanoma; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991,,,,,,,Homo sapiens A549 lung carcinoma cell,0.35,Human SARS coronavirus;SARS-CoV-2,Homo sapiens
HYAL1,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Tumor Progression; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0277695594716545; 0.0387439397151409,,,,,,,,,,
ICA1,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,,,,,yeasx,0.37,Bacillus anthracis,Homo sapiens
ID2,Ovarian Carcinoma; Epithelioma; Squamous cell carcinoma; ovarian neoplasm; Carcinogenesis; Malignant neoplasm of ovary,0.0034602840073026; 0.0149002095788623; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545,,,,,,,Homo sapiens;yeasx,0.4;0.55;0.56,Homo sapiens;Saccharomyces cerevisiae,Homo sapiens;Saccharomyces cerevisiae
IL22RA1,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,Severe generalized junctional epidermolysis bullosa ORPHA:79404; Kindler epidermolysis bullosa ORPHA:2908; Autosomal recessive infantile hypercalcemia ORPHA:300547; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403,0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,,,,
IQGAP2,"Ovarian Carcinoma; Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Brain Tumor, Primary",0.0034602840073026; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.044151975756427,,,,,,,In vitro;yeasx,0.35;0.37;0.46,Bacillus anthracis;Homo sapiens;chemical synthesis,Homo sapiens;ebvg;hcvjf
ISL1,Breast Carcinoma; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis,0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991,,,,,,,,,,
ITGA2,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Malignant neoplasm of ovary; Medulloblastoma,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0277695594716545; 0.0354767239335874,,,"Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Auriculocondylar syndrome ORPHA:137888; Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Myelodysplastic syndrome ORPHA:52688; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Hereditary papillary renal cell carcinoma ORPHA:47044; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Osteofibrous dysplasia ORPHA:488265; PPARG-related familial partial lipodystrophy ORPHA:79083; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Familial primary localized cutaneous amyloidosis ORPHA:353220; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Erythrokeratodermia variabilis ORPHA:317",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111,,,In vitro;ecoli;yeasx,0.35;0.37;0.44;0.56;0.59,Homo sapiens;Mus musculus;chemical synthesis;chick;rat;rots1,Echis multisquamatus;Homo sapiens;Mus musculus;bovin;coxbu
KAT2B,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Colorectal Cancer; Stomach Carcinoma; Pre B-cell acute lymphoblastic leukemia; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Medulloblastoma,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0189794808441368; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0354767239335874,,,,,,,Homo sapiens CD4+ T-cell;Homo sapiens HeLa epitheloid cervical carcinoma cell;Homo sapiens LNCaP caucasian prostate adenocarcinoma cell;Homo sapiens M059JK glioblastoma cell;Homo sapiens U2OS osteosarcoma cell;In vitro;Saccharomyces cerevisiae,0.35;0.4;0.44;0.51;0.66,Homo sapiens;ade05,-;Homo sapiens;ade05;chemical synthesis
KBTBD8,Malignant neoplasm of breast,0.0191435238361999,Breast Cancer,0.0402286636010764,,,,,,,,
KCNN4,Breast Carcinoma,0.0042545616049287,Breast Carcinoma,0.0075861267486594,,,,,,,,
KITLG,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0308703957553632,Anomalous Pulmonary Artery; Anaplastic Carcinoma,0.0075861267486594; 0.0402286636010764,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; SIX2-related frontonasal dysplasia ORPHA:488437; Auriculocondylar syndrome ORPHA:137888; Peters anomaly ORPHA:708; 20p12.3 microdeletion syndrome ORPHA:261295; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Unverricht-Lundborg disease ORPHA:308; Waardenburg syndrome type 2 ORPHA:895; Early-onset nuclear cataract ORPHA:98991; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Autosomal recessive brachyolmia ORPHA:448242; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Craniosynostosis, Boston type ORPHA:1541; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Hereditary papillary renal cell carcinoma ORPHA:47044; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Myopathic Ehlers-Danlos syndrome ORPHA:536516; Nance-Horan syndrome ORPHA:627; Osteofibrous dysplasia ORPHA:488265; PPARG-related familial partial lipodystrophy ORPHA:79083; Parietal foramina with clavicular hypoplasia ORPHA:251290; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; X-linked osteoporosis with fractures ORPHA:391330; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0083744975290613; 0.0092060390928213; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,In vitro,0.44,Homo sapiens,Homo sapiens
KRT13,Breast Carcinoma; Tumor Progression; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast,0.0042545616049287; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999,Esophagus Neoplasm,0.0102679590519094,Autosomal recessive infantile hypercalcemia ORPHA:300547; Bamforth-Lazarus syndrome ORPHA:1226,0.0083045131203191; 0.0180064224283883,,,In vitro;yeasx,0.35;0.56,Homo sapiens;chemical synthesis,Homo sapiens
KRT23,Colorectal Carcinoma; Colorectal Cancer; Adenocarcinoma,0.0034602840073026; 0.0149315928814189; 0.0155921563748247,,,,,,,,,,
LAMA3,Mammary Neoplasms; Ovarian Carcinoma; Stomach Carcinoma; Adenocarcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0387439397151409,,,"Atrial septal defect, ostium primum type ORPHA:99106; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Isolated hyperchlorhidrosis ORPHA:542657; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Myelodysplastic syndrome ORPHA:52688; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Bamforth-Lazarus syndrome ORPHA:1226; Hereditary papillary renal cell carcinoma ORPHA:47044; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Osteofibrous dysplasia ORPHA:488265; PPARG-related familial partial lipodystrophy ORPHA:79083; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Erythrokeratodermia variabilis ORPHA:317",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111,,,Homo sapiens;Homo sapiens HEK293 embryonic kidney cell,0.35;0.4,Homo sapiens;ebvb9,Homo sapiens
LAMP3,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0277695594716545; 0.0387439397151409,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944,0.0180064224283883; 0.0180064224283883,,,Homo sapiens HEK293T embryonic kidney cell,0.35,Homo sapiens,Homo sapiens
LIFR,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Medulloblastoma,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0354767239335874,Congenital Anomalies Of Kidney And Urinary Tract,0.0075861267486594,"Atrial septal defect, ostium primum type ORPHA:99106; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Branchiootic syndrome ORPHA:52429; Myelodysplastic syndrome ORPHA:52688; Brachydactyly type A2 ORPHA:93396; Waardenburg syndrome type 2 ORPHA:895; Bruck syndrome ORPHA:2771; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; Oculocutaneous albinism type 3 ORPHA:79433; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; X-linked osteoporosis with fractures ORPHA:391330; Congenital cataract microcornea with corneal opacity ORPHA:289499; Congenital diaphragmatic hernia ORPHA:2140; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721; BOR syndrome ORPHA:107; Tetralogy of Fallot ORPHA:3303",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0277610005156803,,,Homo sapiens,0.35,ebvb9,Homo sapiens
LPAR5,melanoma; Fibrosarcoma,0.0149315928814189; 0.0191435238361999,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944,0.0180064224283883; 0.0180064224283883,,,,,,
LRIG1,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Squamous cell carcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545,,,,,,,,,,
LZTS1,Colorectal Carcinoma; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Malignant neoplasm of esophagus; Malignant neoplasm of ovary,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0248454592431097; 0.0277695594716545,Esophagus Neoplasm,0.0102679590519094,,,,,,,,
ME1,Breast Carcinoma; Colorectal Cancer; Carcinogenesis; Epithelial ovarian cancer,0.0042545616049287; 0.0149315928814189; 0.0228075668512991; 0.0387439397151409,,,Papillary renal cell carcinoma ORPHA:319298; Unverricht-Lundborg disease ORPHA:308; PPARG-related familial partial lipodystrophy ORPHA:79083,0.0083045131203191; 0.0083744975290613; 0.0180064224283883,,,In vitro;yeasx,0.35;0.68,Homo sapiens,Homo sapiens;chemical synthesis
MICB,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999,,,,,,,,,,
MIR100HG,Breast Carcinoma; Malignant neoplasm of breast; Medulloblastoma,0.0042545616049287; 0.0191435238361999; 0.0354767239335874,,,,,,,,,,
MIR17HG,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Hematopoietic Neoplasms; Medulloblastoma,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0334891258932371; 0.0354767239335874,,,,,,,,,,
MKNK2,Breast Carcinoma; Malignant neoplasm of breast; Medulloblastoma,0.0042545616049287; 0.0191435238361999; 0.0354767239335874,,,,,,,yeasx,0.37,Homo sapiens,Homo sapiens
MT1E,Mammary Neoplasms; Breast Carcinoma; Invasive Ductal Breast Carcinoma; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0191435238361999,,,Hereditary arterial and articular multiple calcification syndrome ORPHA:289601,0.00518481975049,,,,,,
NCEH1,,,,,PPARG-related familial partial lipodystrophy ORPHA:79083,0.0180064224283883,,,Homo sapiens;Homo sapiens A549 lung carcinoma cell;Homo sapiens HEK293T embryonic kidney cell;Homo sapiens QGY7703 hepatocellular carcinoma cell;In vitro,0.35;0.53,Homo sapiens;Human SARS coronavirus;Human coronavirus 229E;Human papillomavirus type 11;Human papillomavirus type 6b;SARS-CoV-2;ade05;canen;chltr;ebvb9,Homo sapiens
NEU1,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Epithelioma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; melanoma; Adenocarcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409,,,,,,,Homo sapiens HEK293T embryonic kidney cell;In vitro,0.35;0.53,Homo sapiens;SARS-CoV-2;chemical synthesis,Homo sapiens
NGFR,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Squamous cell carcinoma; Malignant mesothelioma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Medulloblastoma; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0354767239335874; 0.0387439397151409,,,,,,,,,,
NOLC1,Colorectal Carcinoma; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0387439397151409,,,,,,,Homo sapiens CACO2 Caucasian colon adenocarcinoma cell;In vitro,0.35,SARS-CoV-2;chemical synthesis,Homo sapiens
NR4A2,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0191435238361999,,,,,,,yeasx,0.37,Homo sapiens,Homo sapiens
NRIP1,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Adenocarcinoma; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0155921563748247; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545,Congenital Anomalies Of Kidney And Urinary Tract; Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205,0.0180064224283883; 0.0180064224283883,,,,,,
OGFR,Ovarian Carcinoma; Tumor Progression; Malignant neoplasm of ovary,0.0034602840073026; 0.0149315928814189; 0.0277695594716545,,,,,,,,,,
OIP5,Breast Carcinoma; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus,0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097,,,Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681,0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,Homo sapiens HEK293T embryonic kidney cell;Saccharomyces cerevisiae;yeasx,0.35;0.56;0.67,Homo sapiens,Homo sapiens
P2RX7,Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Tumor Progression; melanoma; Adenocarcinoma; Malignant neoplasm of breast; Carcinogenesis; Hematopoietic Neoplasms,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0228075668512991; 0.0334891258932371,Lymphocytic Leukemia,0.0487679768343083,,,,,,,,
P3H2,Breast Carcinoma; melanoma; Malignant neoplasm of breast,0.0042545616049287; 0.0149315928814189; 0.0191435238361999,Breast Cancer,0.0402286636010764,20p12.3 microdeletion syndrome ORPHA:261295; Autosomal recessive spastic paraplegia type 66 ORPHA:401815,0.0083045131203191; 0.0180064224283883,,,yeasx,0.37,Bacillus anthracis;Homo sapiens,Bacillus anthracis;Homo sapiens
PADI3,Malignant neoplasm of breast; Carcinogenesis,0.0191435238361999; 0.0228075668512991,Breast Cancer,0.0402286636010764,Autosomal recessive infantile hypercalcemia ORPHA:300547; Bamforth-Lazarus syndrome ORPHA:1226,0.0083045131203191; 0.0180064224283883,,,yeasx,0.67,Homo sapiens,Homo sapiens
PBX1,Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Stomach Carcinoma; Retroviridae Infections; melanoma; Squamous cell carcinoma; Pre B-cell acute lymphoblastic leukemia; ovarian neoplasm; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of ovary; Hematopoietic Neoplasms,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0189794808441368; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0334891258932371,Congenital Anomalies Of Kidney And Urinary Tract,0.0075861267486594,Nance-Horan syndrome ORPHA:627; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Matthew-Wood syndrome ORPHA:2470,0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,,,,
PCDH7,,,,,"Atrial septal defect, ostium primum type ORPHA:99106; Peters anomaly ORPHA:708; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Greig cephalopolysyndactyly syndrome ORPHA:380; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Branchiootic syndrome ORPHA:52429; Brachydactyly type A2 ORPHA:93396; Waardenburg syndrome type 2 ORPHA:895; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Nance-Horan syndrome ORPHA:627; Oculocutaneous albinism type 3 ORPHA:79433; Hypoplastic left heart syndrome ORPHA:2248; Matthew-Wood syndrome ORPHA:2470; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721",0.0040361447187818; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,,,,
PDE4B,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,,,,,,,,
PDGFB,Mammary Neoplasms; Breast Carcinoma; melanoma; Malignant mesothelioma; ovarian neoplasm; Fibrosarcoma; Medulloblastoma; Skin carcinoma,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0354767239335874; 0.0482468351695405,,,Dermatofibrosarcoma protuberans ORPHA:31112,0.0180064224283883,,,Escherichia coli;Homo sapiens HEK293T embryonic kidney cell;In vitro,0.35;0.73,Homo sapiens,Homo sapiens
PIR,melanoma,0.0149315928814189,,,,,,,,,,
PLEKHD1,,,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,,,,,,,,
PLK2,"Ovarian Carcinoma; Tumor Progression; Adenocarcinoma; Squamous cell carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Epithelial ovarian cancer",0.0034602840073026; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0228075668512991; 0.0277695594716545; 0.0308703957553632; 0.0387439397151409,Anaplastic Carcinoma,0.0402286636010764,Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Auriculocondylar syndrome ORPHA:137888; Chondrosarcoma ORPHA:55880; Familial progressive hyper- and hypopigmentation ORPHA:280628; Familial progressive hyperpigmentation ORPHA:79146; Neonatal inflammatory skin and bowel disease ORPHA:294023; Pediatric hepatocellular carcinoma ORPHA:33402; Trichorhinophalangeal syndrome type 2 ORPHA:502,0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,Homo sapiens HeLa epitheloid cervical carcinoma cell,0.4,Homo sapiens,Mus musculus
PLSCR4,,,,,"Atrial septal defect, ostium primum type ORPHA:99106; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; 20p12.3 microdeletion syndrome ORPHA:261295; Papillary renal cell carcinoma ORPHA:319298; Waardenburg syndrome type 2 ORPHA:895; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Autosomal recessive brachyolmia ORPHA:448242; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Diaphanospondylodysostosis ORPHA:66637; Familial drusen ORPHA:75376; Hereditary neuropathy with liability to pressure palsies ORPHA:640; Ischiovertebral syndrome ORPHA:85200; Primary CD59 deficiency ORPHA:169464; RIN2 syndrome ORPHA:217335; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Congenital diaphragmatic hernia ORPHA:2140; Piebaldism ORPHA:2884; Rolandic epilepsy-speech dyspraxia syndrome ORPHA:163721",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0092060390928213; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,yeasx,0.37;0.56,Bacillus anthracis;Homo sapiens,Homo sapiens
PPP1R14B,melanoma,0.0149315928814189,,,,,,,,,,
PRMT6,Mammary Neoplasms; Breast Carcinoma; Tumor Progression; melanoma; Malignant neoplasm of breast; Carcinogenesis,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991,,,,,,,Homo sapiens HEK293T embryonic kidney cell;In vitro;yeasx,0.35;0.52;0.56,Homo sapiens;hhv8,Homo sapiens;chemical synthesis
PRR15,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959,0.0180064224283883,,,In vitro;yeasx,0.35;0.44;0.56,HCV77;Homo sapiens;chemical synthesis,Homo sapiens
PRSS23,Breast Carcinoma; Tumor Progression; melanoma; Malignant neoplasm of breast,0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999,,,"Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome ORPHA:306504; Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; Auriculocondylar syndrome ORPHA:137888; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Autosomal recessive brachyolmia ORPHA:448242; Primary CD59 deficiency ORPHA:169464; RIN2 syndrome ORPHA:217335; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Familial primary localized cutaneous amyloidosis ORPHA:353220; Trichorhinophalangeal syndrome type 2 ORPHA:502",0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,,,,
PSMB9,Epithelioma; melanoma; ovarian neoplasm,0.0149002095788623; 0.0149315928814189; 0.0191435238361999,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944,0.0180064224283883; 0.0180064224283883,,,Homo sapiens HEK293T embryonic kidney cell;Saccharomyces cerevisiae,0.37;0.51,Homo sapiens;hcvco,Homo sapiens;hcvco
PURPL,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,,,,,,,,
RBM24,,,,,"Atrial septal defect, ostium secundum type ORPHA:99103; Branchiootic syndrome ORPHA:52429; Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093; Posterior hypospadias ORPHA:95706",0.00518481975049; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,,,,
RGL1,Malignant neoplasm of breast,0.0191435238361999,Breast Cancer,0.0402286636010764,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome ORPHA:79118; RIN2 syndrome ORPHA:217335,0.00518481975049; 0.0180064224283883,,,,,,
RGS6,Mammary Neoplasms; Breast Carcinoma; Tumor Progression; Malignant neoplasm of breast; Carcinogenesis,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991,,,,,,,,,,
RHOBTB3,Tumor Progression,0.0149315928814189,,,Myelodysplastic syndrome ORPHA:52688; Congenital diaphragmatic hernia ORPHA:2140,0.0083045131203191; 0.0180064224283883,,,In vitro,0.44,Homo sapiens;chemical synthesis,Homo sapiens;chemical synthesis
RHOU,Mammary Neoplasms; Stomach Carcinoma; Malignant neoplasm of stomach; Carcinogenesis,0.0034602840073026; 0.0149315928814189; 0.0191435238361999; 0.0228075668512991,Lymphocytic Leukemia,0.0487679768343083,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205,0.0180064224283883; 0.0180064224283883,,,In vitro,0.44,Homo sapiens,chemical synthesis
RPSAP52,,,,,Arnold-Chiari malformation type I ORPHA:268882; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971,0.00518481975049; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111,,,,,,
RTKN2,Breast Carcinoma,0.0042545616049287,Breast Carcinoma,0.0075861267486594,,,,,,,,
S100A14,Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Tumor Progression; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary,0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545,,,Severe generalized junctional epidermolysis bullosa ORPHA:79404; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Kindler epidermolysis bullosa ORPHA:2908; Laryngo-onycho-cutaneous syndrome ORPHA:2407; Autosomal recessive infantile hypercalcemia ORPHA:300547; Neonatal ichthyosis-sclerosing cholangitis syndrome ORPHA:59303; Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome ORPHA:401959; Junctional epidermolysis bullosa with pyloric atresia ORPHA:79403; Erythrokeratodermia variabilis ORPHA:317,0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111,,,,,,
SCG2,melanoma; Adenocarcinoma,0.0149315928814189; 0.0155921563748247,,,Ondine syndrome ORPHA:661,0.020072786018028,,,,,,
SCHIP1,,,,,Ondine syndrome ORPHA:661,0.020072786018028,,,In vitro;yeasx,0.56;0.59,Homo sapiens,Homo sapiens
SCML2,Medulloblastoma,0.0354767239335874,,,,,,,,,,
SETD7,Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991,,,,,,,In vitro,0.44,Homo sapiens,-;chemical synthesis
SHCBP1,Tumor Progression; melanoma; Carcinogenesis,0.0149315928814189; 0.0149315928814189; 0.0228075668512991,,,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Chronic atrial and intestinal dysrhythmia syndrome ORPHA:435988; Congenital dyserythropoietic anemia type III ORPHA:98870; Filippi syndrome ORPHA:3255; Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome ORPHA:444069; Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome ORPHA:439897; Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome ORPHA:500135; Roberts syndrome ORPHA:3103; Stromme syndrome ORPHA:506307; NON RARE IN EUROPE: Lactase non-persistence in adulthood ORPHA:319681; Dedifferentiated liposarcoma ORPHA:99970; Well-differentiated liposarcoma ORPHA:99971,0.0083045131203191; 0.0106988445340883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111,,,Homo sapiens HeLa epitheloid cervical carcinoma cell,0.4,Mus musculus,Homo sapiens
SIX2,Breast Carcinoma; Malignant neoplasm of breast; Carcinogenesis,0.0042545616049287; 0.0191435238361999; 0.0228075668512991,Congenital Anomalies Of Kidney And Urinary Tract,0.0075861267486594,SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Rieger anomaly ORPHA:91483; Bamforth-Lazarus syndrome ORPHA:1226; BOR syndrome ORPHA:107,0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0183145313768111,,,Homo sapiens HEK293T embryonic kidney cell;yeasx,0.37;0.4,Homo sapiens,Homo sapiens
SKAP1,Ovarian Carcinoma; ovarian neoplasm; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0191435238361999; 0.0277695594716545; 0.0387439397151409,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944,0.0180064224283883; 0.0180064224283883,,,,,,
SKIL,melanoma; Squamous cell carcinoma,0.0149315928814189; 0.0182265588252201,,,,,,,yeasx,0.56,Homo sapiens,Homo sapiens
SLC22A18,Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Carcinogenesis; Malignant neoplasm of esophagus,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,Hereditary breast cancer ORPHA:227535,0.0106988445340883,,,Homo sapiens;In vitro,0.35,Homo sapiens;Human papillomavirus type 11;Human papillomavirus type 6b;ebvb9,Homo sapiens
SMAD6,Ovarian Carcinoma; Squamous cell carcinoma; Carcinogenesis; Malignant neoplasm of ovary,0.0034602840073026; 0.0182265588252201; 0.0228075668512991; 0.0277695594716545,,,"Atrial septal defect, ostium secundum type ORPHA:99103; Ulnar-mammary syndrome ORPHA:3138; Myelodysplastic syndrome ORPHA:52688; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; Tetralogy of Fallot ORPHA:3303",0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0277610005156803,,,Chlorocebus aethiops;Homo sapiens;Homo sapiens HEK293T embryonic kidney cell;Saccharomyces cerevisiae,0.35;0.4;0.51,Homo sapiens;Mus musculus,Homo sapiens
SMAD7,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Retroviridae Infections; melanoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409,,,,,,,Homo sapiens,0.4,Homo sapiens,Homo sapiens
SNAI2,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Epithelioma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Epithelial ovarian cancer; Skin carcinoma,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0387439397151409; 0.0482468351695405,Anomalous Pulmonary Artery; Breast Carcinoma; Esophagus Neoplasm; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,"Atrial septal defect, ostium primum type ORPHA:99106; Arnold-Chiari malformation type I ORPHA:268882; Autosomal recessive nail dysplasia ORPHA:280654; Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; SIX2-related frontonasal dysplasia ORPHA:488437; Peters anomaly ORPHA:708; Atrial septal defect, ostium secundum type ORPHA:99103; Familial porencephaly ORPHA:99810; 20p12.3 microdeletion syndrome ORPHA:261295; Chondrosarcoma ORPHA:55880; Greig cephalopolysyndactyly syndrome ORPHA:380; Isolated hyperchlorhidrosis ORPHA:542657; Pallister-Hall syndrome ORPHA:672; Polysyndactyly ORPHA:93338; Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome ORPHA:420584; Sensorineural deafness with dilated cardiomyopathy ORPHA:217622; Tibial hemimelia ORPHA:93322; Ulnar-mammary syndrome ORPHA:3138; Axenfeld anomaly ORPHA:98978; Axenfeld-Rieger syndrome ORPHA:782; Branchiootic syndrome ORPHA:52429; Congenital short bowel syndrome ORPHA:2301; Papillary renal cell carcinoma ORPHA:319298; Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome ORPHA:71289; Rieger anomaly ORPHA:91483; Brachydactyly type A2 ORPHA:93396; Unverricht-Lundborg disease ORPHA:308; Waardenburg syndrome type 2 ORPHA:895; Early-onset nuclear cataract ORPHA:98991; Bruck syndrome ORPHA:2771; Autosomal recessive spastic paraplegia type 66 ORPHA:401815; CHST3-related skeletal dysplasia ORPHA:263463; COL4A1-related familial vascular leukoencephalopathy ORPHA:36383; Cobblestone lissencephaly without muscular or ocular involvement ORPHA:352682; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Diaphanospondylodysostosis ORPHA:66637; FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome ORPHA:404451; Familial drusen ORPHA:75376; Familial schizencephaly ORPHA:481986; GAPO syndrome ORPHA:2067; HANAC syndrome ORPHA:73229; Ischiovertebral syndrome ORPHA:85200; Lethal occipital encephalocele-skeletal dysplasia syndrome ORPHA:293925; Mandibulofacial dysostosis with alopecia ORPHA:443995; Myopathic Ehlers-Danlos syndrome ORPHA:536516; NON RARE IN EUROPE: Exfoliation syndrome ORPHA:529819; Oculocutaneous albinism type 3 ORPHA:79433; Pancreatic hypoplasia-diabetes-congenital heart disease syndrome ORPHA:2255; Pontine autosomal dominant microangiopathy with leukoencephalopathy ORPHA:477749; Primary CD59 deficiency ORPHA:169464; Retinal arterial tortuosity ORPHA:75326; Sorsby pseudoinflammatory fundus dystrophy ORPHA:59181; Steel syndrome ORPHA:438117; Synpolydactyly type 2 ORPHA:295197; Uveal coloboma-cleft lip and palate-intellectual disability ORPHA:1473; Woolly hair-palmoplantar keratoderma syndrome ORPHA:420686; X-linked osteoporosis with fractures ORPHA:391330; Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form ORPHA:79408; Congenital diaphragmatic hernia ORPHA:2140; Familial primary localized cutaneous amyloidosis ORPHA:353220; Hypoplastic left heart syndrome ORPHA:2248; Piebaldism ORPHA:2884; Posterior hypospadias ORPHA:95706; Trichorhinophalangeal syndrome type 2 ORPHA:502; BOR syndrome ORPHA:107; Erythrokeratodermia variabilis ORPHA:317; Ondine syndrome ORPHA:661",0.0040361447187818; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0083744975290613; 0.0083744975290613; 0.0092060390928213; 0.0179885731122231; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0183145313768111; 0.0183145313768111; 0.020072786018028,,,Homo sapiens MDA-MB-468 mammary gland adenocarcinoma cell,0.35,Homo sapiens,Homo sapiens
SNCG,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Carcinoma, Spindle-Cell; Epithelial ovarian cancer",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0308703957553632; 0.0387439397151409,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Anaplastic Carcinoma; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764; 0.0402286636010764,Autosomal dominant Charcot-Marie-Tooth disease type 2L ORPHA:99945; Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome ORPHA:476093,0.0180064224283883; 0.0180064224283883,,,Homo sapiens HEK293 embryonic kidney cell,0.4,Homo sapiens,Homo sapiens
SORBS1,Colorectal Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Colorectal Cancer; Malignant neoplasm of breast; Epithelial ovarian cancer,0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0191435238361999; 0.0387439397151409,Breast Cancer,0.0402286636010764,,,,,In vitro;chinese hamster ovary cell line,0.35;0.4,Homo sapiens;chemical synthesis;crigr,Homo sapiens;Mycobacterium tuberculosis (strain ATCC 35801 / TMC 107 / Erdman)
SORL1,Colorectal Cancer; Malignant neoplasm of breast,0.0149315928814189; 0.0191435238361999,Breast Cancer,0.0402286636010764,,,,,Homo sapiens HCT116 colon carcinoma cell;Homo sapiens HEK293T embryonic kidney cell;In vitro;yeasx,0.35;0.4;0.56;0.81,Homo sapiens,Homo sapiens;chemical synthesis
SORT1,Colorectal Carcinoma; Breast Carcinoma; Colorectal Cancer; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0191435238361999,,,Familial multiple nevi flammei ORPHA:624; Sturge-Weber syndrome ORPHA:3205,0.0180064224283883; 0.0180064224283883,,,Homo sapiens;Homo sapiens A549 lung carcinoma cell;In vitro,0.35;0.4;0.44;0.56;0.68,Homo sapiens;Human SARS coronavirus;SARS-CoV-2;ade05;chemical synthesis;ebvb9,Homo sapiens;chemical synthesis
SPAG1,Carcinogenesis,0.0228075668512991,,,,,,,Homo sapiens HEK293T embryonic kidney cell,0.35,Homo sapiens,Homo sapiens
SPC25,,,,,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome ORPHA:221043; Hereditary breast cancer ORPHA:227535; Roberts syndrome ORPHA:3103,0.0083045131203191; 0.0106988445340883; 0.0180064224283883,,,In vitro,0.35,chemical synthesis,Homo sapiens
STN1,Colorectal Carcinoma; Colorectal Cancer; melanoma; Epithelial ovarian cancer,0.0034602840073026; 0.0149315928814189; 0.0149315928814189; 0.0387439397151409,,,,,,,,,,
SULT1A1,"Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Urologic Neoplasms; Brain Tumor, Primary; Cancer of Urinary Tract",0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0314665934969085; 0.044151975756427; 0.0492766532827251,Breast Carcinoma; Urinary Tract Cancer; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,,,,,Homo sapiens HEK293T embryonic kidney cell;yeasx,0.35;0.37,Homo sapiens,Bacillus anthracis;Homo sapiens
SUSD4,Breast Carcinoma; Tumor Progression; Malignant neoplasm of breast,0.0042545616049287; 0.0149315928814189; 0.0191435238361999,,,,,,,,,,
TET1,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Hematopoietic Neoplasms; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0334891258932371; 0.0387439397151409,,,,,,,,,,
TFAP4,Colorectal Carcinoma; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,,,,,Homo sapiens HCT116 colon carcinoma cell;In vitro;yeasx,0.35;0.37;0.58,Homo sapiens,Homo sapiens
TGM2,"Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Proliferative vitreoretinopathy; Squamous cell carcinoma; Esophageal Neoplasms; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Epithelial ovarian cancer; Brain Tumor, Primary",0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0387439397151409; 0.044151975756427,Breast Carcinoma; Esophagus Neoplasm; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0102679590519094; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,"Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Autosomal recessive brachyolmia ORPHA:448242; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; Familial drusen ORPHA:75376; PPARG-related familial partial lipodystrophy ORPHA:79083; Primary CD59 deficiency ORPHA:169464; RIN2 syndrome ORPHA:217335; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282",0.00518481975049; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,Homo sapiens HLMVEC lung microvascular endothelial cell;In vitro;yeasx,0.35;0.37;0.44;0.76,Homo sapiens;chemical synthesis,Homo sapiens;chemical synthesis
THBS1,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Invasive Ductal Breast Carcinoma; Colorectal Cancer; Tumor Progression; Stomach Carcinoma; melanoma; Adenocarcinoma; Squamous cell carcinoma; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of ovary; Medulloblastoma; Epithelial ovarian cancer; Skin carcinoma; Cancer of Urinary Tract,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0277695594716545; 0.0354767239335874; 0.0387439397151409; 0.0482468351695405; 0.0492766532827251,Breast Carcinoma; Marfan Syndrome; Mammary Neoplasms; Breast Cancer,0.0075861267486594; 0.0133304506157067; 0.0155248163763686; 0.0402286636010764,"Hereditary arterial and articular multiple calcification syndrome ORPHA:289601; Auriculocondylar syndrome ORPHA:137888; Benign recurrent intrahepatic cholestasis type 1 ORPHA:99960; Chondrosarcoma ORPHA:55880; Congenital short bowel syndrome ORPHA:2301; Autosomal recessive brachyolmia ORPHA:448242; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465; RIN2 syndrome ORPHA:217335; Spondyloepimetaphyseal dysplasia, PAPSS2 type ORPHA:93282; Familial primary localized cutaneous amyloidosis ORPHA:353220; Trichorhinophalangeal syndrome type 2 ORPHA:502",0.00518481975049; 0.00518481975049; 0.0083045131203191; 0.0083045131203191; 0.0083045131203191; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,Homo sapiens HLMVEC lung microvascular endothelial cell;Homo sapiens blood plasma;In vitro;Saccharomyces cerevisiae,0.35;0.37;0.44;0.61;0.7,Homo sapiens;chemical synthesis;staa8,Homo sapiens;chemical synthesis;hcvco
TIMP2,Colorectal Carcinoma; Mammary Neoplasms; Ovarian Carcinoma; Breast Carcinoma; Invasive carcinoma of breast; Epithelioma; Colorectal Cancer; Stomach Carcinoma; Retroviridae Infections; melanoma; Adenocarcinoma; Squamous cell carcinoma; Esophageal Neoplasms; Malignant mesothelioma; ovarian neoplasm; Malignant neoplasm of breast; Fibrosarcoma; Malignant neoplasm of stomach; Carcinogenesis; Malignant neoplasm of esophagus; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149002095788623; 0.0149002095788623; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0149315928814189; 0.0155921563748247; 0.0182265588252201; 0.0182265588252201; 0.0182265588252201; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991; 0.0248454592431097; 0.0277695594716545; 0.0387439397151409,,,Unverricht-Lundborg disease ORPHA:308; Acute inflammatory demyelinating polyradiculoneuropathy ORPHA:98916; Charcot-Marie-Tooth disease type 1A ORPHA:101081; Charcot-Marie-Tooth disease type 1E ORPHA:90658; Familial multiple nevi flammei ORPHA:624; Hereditary neuropathy with liability to pressure palsies ORPHA:640; RIN2 syndrome ORPHA:217335; Sturge-Weber syndrome ORPHA:3205,0.0083744975290613; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,Homo sapiens HEK293 embryonic kidney cell,0.4,Homo sapiens,Homo sapiens
TNFSF9,Colorectal Carcinoma; Ovarian Carcinoma; Colorectal Cancer; Adenocarcinoma; Malignant neoplasm of stomach; Epithelial ovarian cancer,0.0034602840073026; 0.0034602840073026; 0.0149315928814189; 0.0155921563748247; 0.0191435238361999; 0.0387439397151409,,,,,,,Homo sapiens A549 lung carcinoma cell,0.35,Human SARS coronavirus;SARS-CoV-2,Homo sapiens
TPM4,Invasive Ductal Breast Carcinoma; Esophageal Neoplasms; Malignant neoplasm of breast; Malignant neoplasm of esophagus,0.0149002095788623; 0.0182265588252201; 0.0191435238361999; 0.0248454592431097,Esophagus Neoplasm; Breast Cancer,0.0102679590519094; 0.0402286636010764,Congenital short bowel syndrome ORPHA:2301; Congenital plasminogen activator inhibitor type 1 deficiency ORPHA:465,0.0083045131203191; 0.0180064224283883,,,In vitro;yeasx,0.35;0.49,Homo sapiens;chemical synthesis,Homo sapiens;hcvjf
TRAK2,Breast Carcinoma,0.0042545616049287,Breast Carcinoma,0.0075861267486594,,,,,yeasx,0.37,Homo sapiens,Yersinia pestis
TRIB3,Colorectal Carcinoma; Mammary Neoplasms; Breast Carcinoma; Colorectal Cancer; Stomach Carcinoma; Malignant neoplasm of breast; Malignant neoplasm of stomach; Carcinogenesis,0.0034602840073026; 0.0034602840073026; 0.0042545616049287; 0.0149315928814189; 0.0149315928814189; 0.0191435238361999; 0.0191435238361999; 0.0228075668512991,,,,,,,yeasx,0.56,Homo sapiens,Homo sapiens
TSC22D1,"Mammary Neoplasms; Carcinogenesis; Carcinoma, Spindle-Cell",0.0034602840073026; 0.0228075668512991; 0.0308703957553632,Anaplastic Carcinoma,0.0402286636010764,Familial multiple nevi flammei ORPHA:624; Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta ORPHA:566243; Sturge-Weber syndrome ORPHA:3205,0.0180064224283883; 0.0180064224283883; 0.0180064224283883,,,Homo sapiens HEK293 embryonic kidney cell;Homo sapiens HEK293flp-in T-REX embryonic kidney cell;In vitro;Saccharomyces cerevisiae;yeasx,0.4;0.46;0.55,Homo sapiens,Homo sapiens
UQCC1,Malignant neoplasm of breast,0.0191435238361999,Breast Cancer,0.0402286636010764,,,,,Homo sapiens HEK293T embryonic kidney cell;Homo sapiens HEK293flp-in embryonic kidney cell,0.27;0.35,Human SARS coronavirus;cioin,Homo sapiens
VGLL3,Ovarian Carcinoma; Breast Carcinoma; Carcinogenesis; Malignant neoplasm of ovary; Epithelial ovarian cancer,0.0034602840073026; 0.0042545616049287; 0.0228075668512991; 0.0277695594716545; 0.0387439397151409,Breast Carcinoma,0.0075861267486594,Congenital short bowel syndrome ORPHA:2301,0.0083045131203191,,,Homo sapiens HEK293T embryonic kidney cell;yeasx,0.56;0.6,Homo sapiens,Homo sapiens
WNT16,Mammary Neoplasms; Colorectal Cancer,0.0034602840073026; 0.0149315928814189,,,,,,,,,,
WNT9A,Mammary Neoplasms,0.0034602840073026,,,SIX2-related frontonasal dysplasia ORPHA:488437,0.00518481975049,,,,,,
ZBED2,,,,,Odonto-onycho-dermal dysplasia ORPHA:2721; Schopf-Schulz-Passarge syndrome ORPHA:50944,0.0180064224283883; 0.0180064224283883,,,,,,
ZBTB18,Medulloblastoma,0.0354767239335874,,,,,,,Homo sapiens SNB-19 glioblastoma cell;Homo sapiens glioblastoma,0.35;0.4;0.53,Homo sapiens,Homo sapiens
ZCCHC12,,,Esophagus Neoplasm,0.0102679590519094,,,,,,,,
ZNF703,Mammary Neoplasms; Breast Carcinoma; Malignant neoplasm of breast,0.0034602840073026; 0.0042545616049287; 0.0191435238361999,,,"Craniosynostosis, Boston type ORPHA:1541; Parietal foramina with clavicular hypoplasia ORPHA:251290",0.0180064224283883; 0.0180064224283883,,,Homo sapiens HEK293T embryonic kidney cell,0.35,Homo sapiens,Homo sapiens
